Investor Presentaiton

Major R&D Milestones (5DXd-ADCS 1) Project ENHERTU® As of Jul 2023 BC . . Target Indication [phase, study name] HER2 low, post chemo [Ph3, DESTINY-Breast04] HER2 low, chemo naïve [Ph3, DESTINY-Breast06] HER2+, 1L [Ph3, DESTINY-Breast09] HER2+, Neoadjuvant [Ph3, DESTINY-Breast11] FY2023 FY2024 H1 H2 ⚫ Approved (China) • ⚫ TLR anticipated . ⚫ TLR anticipated ⚫ TLR anticipated . HER2 mutant, 2L • Approval anticipated (JP) [Ph2, DESTINY-Lung01, 02] • Approval anticipated (EU) NSCLC • HER2 mutant, 1L ⚫ TLR anticipated [Ph3, DESTINY-Lung04] Bold: update from FY2022 Q4 BC: breast cancer, HR: hormone receptor, NSCLC: non-small cell lung cancer, TLR: top line results Timeline indicated is based on the current forecast and subject to change Daiichi-Sankyo 32

View entire presentation